VolitionRx Limited has announced proof-of-concept data showing its Capture-Seq liquid biopsy technology achieved over 95% sensitivity for detecting stage I and II cancers with 95% specificity in a blinded validation cohort. The study included 81 subjects and demonstrated detection rates of 94% for stage I cancers and 96% for stage II cancers, with overall sensitivity of 93% and specificity of 95%.
The technology's performance in early-stage cancer detection represents a significant advancement in the field of liquid biopsy diagnostics. Early detection is crucial for improving cancer survival rates, as stage I and II cancers are typically more treatable than later-stage malignancies. The high sensitivity and specificity rates suggest the technology could potentially identify cancers before symptoms appear, allowing for earlier intervention and better patient outcomes.
Capture-Seq is designed to enrich and purify circulating tumor DNA for analysis, which may support applications in multi-cancer early detection and minimal residual disease monitoring. This approach represents a less invasive alternative to traditional tissue biopsies and could make cancer screening more accessible and acceptable to patients. The company noted the technology targets an estimated $36 billion total addressable market and is currently the subject of discussions with potential licensing and diagnostic partners to accelerate development and commercialization.
The implications of this technology extend beyond individual patient care to broader healthcare systems. Earlier cancer detection could reduce treatment costs by identifying cancers at more treatable stages and potentially decrease mortality rates. For more information about VolitionRx, visit https://volition.com/. The company's research and development activities are centered in Belgium, with additional facilities in the United States and London.
Volition is a multi-national company focused on advancing the science of epigenetics and developing simple, cost-effective blood tests to help detect and monitor a range of diseases. The company's dedication to earlier detection and monitoring has the potential not only to prolong the life of patients but also to improve their quality of life. The full press release containing these findings can be accessed at https://ibn.fm/ktVDF.
